Ser287

Site Information
RRRsLRRsNsIsksP SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3191872

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 )
Disease tissue studied:	breast cancer ( 1 ) , leukemia ( 2 ) , acute myelogenous leukemia ( 2 ) , lung cancer ( 1 ) , non-small cell lung cancer ( 1 )
Relevant cell line - cell type - tissue:	BT-549 (breast cell) ( 1 ) , Calu 6 (pulmonary) ( 1 ) , H2009 (pulmonary) ( 1 ) , H2077 (pulmonary) ( 1 ) , H2887 (pulmonary) ( 1 ) , H322M (pulmonary) ( 1 ) , HCC1359 (pulmonary) ( 1 ) , HCC1937 (breast cell) ( 1 ) , HCC366 (pulmonary) ( 1 ) , HCC4006 (pulmonary) ( 1 ) , HCC78 (pulmonary) ( 1 ) , HCT116 (intestinal) ( 3 ) , HeLa (cervical) ( 7 ) , HeLa S3 (cervical) ( 6 ) , HOP62 (pulmonary) ( 1 ) , Jurkat (T lymphocyte) ( 4 , 5 ) , KG-1 (myeloid) ( 2 ) , MCF-7 (breast cell) ( 1 ) , MDA-MB-231 (breast cell) ( 1 ) , MV4-11 (macrophage) ( 3 ) , NCI-H1395 (pulmonary) ( 1 ) , NCI-H1568 (pulmonary) ( 1 ) , NCI-H1648 (pulmonary) ( 1 ) , NCI-H2030 (pulmonary) ( 1 ) , NCI-H322 (pulmonary) ( 1 ) , NCI-H520 (squamous) ( 1 ) , NCI-H647 (pulmonary) ( 1 ) , PC9 (pulmonary) ( 1 )

Upstream Regulation
Treatments:	nocodazole ( 6 ) , thymidine ( 6 )

References
1	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
2	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
3	Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64 19369195 Curated Info
4	Zhou J (2009) CST Curation Set: 5904; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
5	Zhou J (2009) CST Curation Set: 5905; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985 Curated Info
6	Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48 18691976 Curated Info
7	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info